2021
Best Practices for Spatial Profiling for Breast Cancer Research with the GeoMx® Digital Spatial Profiler
Bergholtz H, Carter JM, Cesano A, Cheang MCU, Church SE, Divakar P, Fuhrman CA, Goel S, Gong J, Guerriero JL, Hoang ML, Hwang ES, Kuasne H, Lee J, Liang Y, Mittendorf EA, Perez J, Prat A, Pusztai L, Reeves JW, Riazalhosseini Y, Richer JK, Sahin Ö, Sato H, Schlam I, Sørlie T, Stover DG, Swain SM, Swarbrick A, Thompson EA, Tolaney SM, Warren SE, Consortium O. Best Practices for Spatial Profiling for Breast Cancer Research with the GeoMx® Digital Spatial Profiler. Cancers 2021, 13: 4456. PMID: 34503266, PMCID: PMC8431590, DOI: 10.3390/cancers13174456.Peer-Reviewed Original ResearchWhole transcriptome levelDigital Spatial ProfilerSpatial profilingTranscriptome levelRNA profilingRNA transcriptsTumor microenvironmentMolecular diversityProtein profilingCancer researchIntegration of datasetsGeoMx Digital Spatial ProfilerProfilingCell populationsMouse samplesBiomarker discoveryBreast tumor microenvironmentBreast Cancer ConsortiumCancer researchers
2015
Tumor profiling and the incidentalome: patient decisions and risks
Hofstatter E, Mehra K, Yushak M, Pusztai L. Tumor profiling and the incidentalome: patient decisions and risks. Future Oncology 2015, 11: 3299-3305. PMID: 26562094, DOI: 10.2217/fon.15.260.BooksConceptsTumor profilingField of oncologyTumor DNA sequencesOncology patientsIncidental discoveryPatient educationPatient's perspectivePatient decisionOncology communityClinical implicationsPatient healthGermline mutationsCancer medicineGenetic sequencingCancer therapyTherapyPotential riskRiskHealthPatientsIncidentalomeMainstayDiseaseOncologyProfiling
2009
Metastatic gene signatures and emerging novel prognostic tests in the management of early stage breast cancer
Tordai A, Liedtke C, Pusztai L. Metastatic gene signatures and emerging novel prognostic tests in the management of early stage breast cancer. Clinical & Experimental Metastasis 2009, 26: 625-632. PMID: 19381845, DOI: 10.1007/s10585-009-9261-z.Peer-Reviewed Original ResearchConceptsMetastatic gene signatureGene expression studiesGene expression profilingDistinct neoplastic diseasesExpression profilingDNA microarraysExpression studiesGene expressionMRNA transcriptsGene signatureSingle experimentNovel diagnostic assaysTranscriptsDiagnostic assaysNovel prognostic testsMicroarrayProfilingExpression
2008
Molecular Pathology and Transcriptional Profiling in Early Drug Development
Liedtke C, Pusztai L, Symmans W. Molecular Pathology and Transcriptional Profiling in Early Drug Development. 2008, 47-84. DOI: 10.1002/9780470475959.ch3.Peer-Reviewed Original ResearchNeoadjuvant chemotherapyClinical settingMultigene predictorsBiomarker developmentClinical drugsIntroduction BiomarkersTranscriptional profilingEarly drug developmentMolecular pathologyBiomarkersChanging ParadigmChemotherapyDrug developmentNovel toolDrugsIntriguing modelPredictorsSettingPathologyProfiling
2003
Molecular profiles of invasive mucinous and ductal carcinomas of the breast a molecular case study
Pusztai L, Sotiriou C, Buchholz TA, Meric F, Symmans WF, Esteva FJ, Sahin A, Liu ET, Hortobagi GN. Molecular profiles of invasive mucinous and ductal carcinomas of the breast a molecular case study. Cancer Genetics 2003, 141: 148-153. PMID: 12606133, DOI: 10.1016/s0165-4608(02)00737-9.Peer-Reviewed Original ResearchConceptsExpression profilingComprehensive genetic analysisExpression of enzymesCDNA microarrayGenetic analysisMolecular case studyExpression profilesInhibitory genesNovel pathwayTumor phenotypeMolecular profileTherapeutic targetPhenotypeTarget therapeuticsBilateral cancerHistologic subclassificationDuctal carcinomaDifferent histologyProfilingHuman backgroundInvasive tumorsMucin productionCellular infiltrationMucinous phenotypeMolecular classification